One such study is Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT2 Inhibitors 3 (CVD-REAL 3) [13], which included more than 71,000 type 2 diabetes patients across five countries. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.